Detalhe da pesquisa
1.
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Ann Rheum Dis
; 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641124
2.
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Antimicrob Agents Chemother
; 61(7)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507108
3.
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Antimicrob Agents Chemother
; 61(1)2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799203
4.
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.
Gastroenterology
; 160(7): 2595-2598.e3, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662385
5.
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
J Antimicrob Chemother
; 72(3): 820-828, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27999038
6.
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Lancet Gastroenterol Hepatol
; 7(11): 1024-1035, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075249
7.
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.
J Virus Erad
; 5(1): 10-22, 2019 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30800421